Since ATO has shown remarkable potency in enhancing the structural stability of p53 [20, 43], it would be worthwhile to investigate whether ATO can also abrogate oncogenic GOF of structural p53 mutants, in addition to restoring tumor-suppressive function, thereby contributing to the observed survival benefit in W/+ LFS mice. The gene discussed is TP53; the disease is neoplasm.